Doxazosin Tablets Recalled Due to Manufacturing Process Deviations
Preferred Pharmaceuticals is recalling Doxazosin Tablets, USP, 4 mg (lot L1522V, expiration 4/30/2025) due to current Good Manufacturing Practice deviations discovered during FDA inspection of the manufacturer, Accord Healthcare. The product was distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall for manufacturing process deviations with no reported illnesses or injuries. This is a precautionary recall based on manufacturing compliance deficiency; without an identified specific hazard or patient harm reported, it meets the Moderate severity threshold.
Plain-English summary
Preferred Pharmaceuticals, Inc. is recalling Doxazosin Tablets, USP, 4 mg in 100-count bottles (NDC 68788-7149-1) from lot L1522V with an expiration date of April 30, 2025. The recall was issued due to current Good Manufacturing Practice (cGMP) deviations identified at the manufacturing facility, Accord Healthcare, Inc. in Durham, North Carolina during an FDA inspection.
Doxazosin is a prescription medication used to treat high blood pressure and urinary symptoms associated with benign prostatic hyperplasia. The cGMP deviations indicate that the manufacturing process did not meet established pharmaceutical quality standards.
The affected product was distributed nationwide. Patients currently taking Doxazosin from the recalled lot should contact their healthcare provider or pharmacist for guidance regarding continued use or alternatives.
The recalled product
- Product
- Doxazosin Tablets, USP, 4 mg, 100-count bottle, Rx only, Manufactured: Accord Healthcare, Inc., Durham, NC 27703, NDC 68788-7149-1
- Manufacturer
- Preferred Pharmaceuticals, Inc.
- Category
- Drug — Prescription Tablet
- Hazard
- manufacturing-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot: L1522V
- Exp 4/30/2025.
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27